References
- Wallin M, Kurtzke J. Neurocysticercosis in the United States: review of an important emerging infection. Neurology63, 1559–1564 (2004).
- Carpio A, Placencia M, Santillán F, Escobar A. A proposal for classification of neurocysticercosis. Can. J. Neurol. Sci.21(1), 43–47 (1994).
- Escobar A. The pathology of neurocysticercosis. In: Cysticercosis of the Central Nervous System. Palacios E, Rodriquez-Carbajal J, Taveras JM (Eds). Charles C Thomas, Springfield, IL, USA 27–54 (1983).
- Del Brutto OH, Rajshekhar V, White AC Jr et al. Proposed diagnostic criteria for neurocysticercosis. Neurology57(2), 177–183 (2001).
- Garg RK. Diagnostic criteria for neurocysticercosis: some modifications are needed for Indian patients. Neurol. India52(2), 171–177 (2004).
- Nash TE, Singh G, White AC et al. Treatment of neurocysticercosis – current status and future research needs. Neurology67(7), 1120–1127 (2006).
- Nash TE. Human case management and treatment of cysticercosis. Acta Trop.87(1), 61–69 (2003).
- Del Brutto OH, Roos KL, Coffey CS, García HH. Meta-analysis: cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann. Intern. Med.145(1), 43–51 (2006).
- Matthaiou DK, Panos G, Adamidi ES, Falagas ME. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl. Trop. Dis.2(3), e194 (2008).
- Carpio A, Kelvin EA, Bagiella E et al.; Neurocysticercosis Group TE. The effects of albendazole treatment on neurocysticercosis: a randomized controlled trial. J. Neurol. Neurosurg. Psychiatry DOI: 10.1136/jnnp.2008.144899 (2008) (Epub ahead of print).
- Garcia HH, Pretell EJ, Gilman RH et al. A trial of antiparasitic treatment to reduce the rate of seizures due to cerebral cysticercosis. N. Engl. J. Med.350(3), 249–258 (2004).
- Das K, Mondal GP, Banerjee M, Mukherjee BB, Singh OP. Role of antiparasitic therapy for seizures and resolution of lesions in neurocysticercosis patients: an 8 year randomised study. J. Clin. Neurosci.14(12), 1172–1177 (2007).
- Göngora-Rivera F, Soto-Hernández JL, González Esquivel D et al. Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology66(3), 436–438 (2006).
- Mitre E, Talaat KR, Sperling MR, Nash TE. Methotrexate as a corticosteroid-sparing agent in complicated neurocysticercosis. Clin. Infect. Dis.44(4), 549–553 (2007).
- Wadia N, Desai S, Bhatt M. Disseminated cysticercosis. New observations, including CT scan findings and experience with treatment by praziquantel. Brain (111), 597–614 (1988).
- Diazgranados-Sanchez JA, Barrios-Arrazola G, Costa JL, Burbano-Pabon J, Pinzon-Bedoya J. Ivermectin as a therapeutic alternative in neurocysticercosis that is resistant to conventional pharmacological treatment. Rev. Neurol.46(11), 671–674 (2008).